282 related articles for article (PubMed ID: 23287624)
21. Cytarabine dose for acute myeloid leukemia.
Mori J; Tsubokura M; Kami M
N Engl J Med; 2011 Jun; 364(22):2166-7; author reply 2168-9. PubMed ID: 21631342
[No Abstract] [Full Text] [Related]
22. Evidence for sinoatrial blockade associated with high dose cytarabine therapy.
Stamatopoulos K; Kanellopoulou G; Vaiopoulos G; Stamatellos G; Yataganas X
Leuk Res; 1998 Aug; 22(8):759-61. PubMed ID: 9680105
[TBL] [Abstract][Full Text] [Related]
23. Isolated Bilateral Ear and Scalp Rash After Cytarabine Therapy for Acute Myelogenous Leukemia: A Report and Literature Review.
Waseem H; Henriquez Felipe C; Hashmi AT; Ansar M; Batool A; Saverimuthu A; Kamholz SL
Am J Ther; 2019; 26(5):e653-e655. PubMed ID: 30418222
[No Abstract] [Full Text] [Related]
24. Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: a pharmacologically based regimen.
Sternberg DW; Aird W; Neuberg D; Thompson L; MacNeill K; Amrein P; Shulman LN
Cancer; 2000 May; 88(9):2037-41. PubMed ID: 10813714
[TBL] [Abstract][Full Text] [Related]
25. Pharmacodynamics of cytarabine induced leucopenia: a retrospective cohort study.
Shepshelovich D; Edel Y; Goldvaser H; Dujovny T; Wolach O; Raanani P
Br J Clin Pharmacol; 2015 Apr; 79(4):685-91. PubMed ID: 25303309
[TBL] [Abstract][Full Text] [Related]
26. Comparison of Mitoxantrone in Combination with Intermediate-dose Cytarabine versus High-dose Cytarabine as Consolidation Therapies for Young Non-APL Acute Myeloid Leukemia Patients with Favorable and Intermediate Cytogenetics.
Zhou JH; Lin HQ; Shen Q; Hu LN; Li GQ; Sun XF; Zhang XY
Curr Med Sci; 2018 Feb; 38(1):51-57. PubMed ID: 30074151
[TBL] [Abstract][Full Text] [Related]
27. High dose cytarabine in acute myelogenous leukemia.
Zittoun R
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():38-42. PubMed ID: 2653516
[No Abstract] [Full Text] [Related]
28. Cladribine in the remission induction of adult acute myeloid leukemia: where do we stand?
Qasrawi A; Bahaj W; Qasrawi L; Abughanimeh O; Foxworth J; Gaur R
Ann Hematol; 2019 Mar; 98(3):561-579. PubMed ID: 30470874
[TBL] [Abstract][Full Text] [Related]
29. Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine.
Pabst T; Vellenga E; van Putten W; Schouten HC; Graux C; Vekemans MC; Biemond B; Sonneveld P; Passweg J; Verdonck L; Legdeur MC; Theobald M; Jacky E; Bargetzi M; Maertens J; Ossenkoppele GJ; Löwenberg B; ; ;
Blood; 2012 Jun; 119(23):5367-73. PubMed ID: 22422824
[TBL] [Abstract][Full Text] [Related]
30. Neutropenia-associated outcomes in adults with acute myeloid leukemia receiving cytarabine consolidation chemotherapy with or without granulocyte colony-stimulating factor.
Bradley AM; Deal AM; Buie LW; van Deventer H
Pharmacotherapy; 2012 Dec; 32(12):1070-7. PubMed ID: 23208834
[TBL] [Abstract][Full Text] [Related]
31. Clinical heterogeneity under induction with different dosages of cytarabine in core binding factor acute myeloid leukaemia.
Wang B; Zhang J; Hua X; Li H; Wang Z; Yang B
Sci Rep; 2020 Jan; 10(1):685. PubMed ID: 31959790
[TBL] [Abstract][Full Text] [Related]
32. Intermediate dose cytarabine improves survival and relapse-free rate compared with standard-dose cytarabine as post-remission treatment for acute myeloid leukemia: A retrospection study.
Ye L; Gao L; Cheng Q; Guo F; He L; Yuan T; Zhu M; Ma Y; Pan M; Chu X; Ding M; Yu G
Medicine (Baltimore); 2021 Jan; 100(3):e24273. PubMed ID: 33546048
[TBL] [Abstract][Full Text] [Related]
33. Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives.
Guolo F; Minetto P; Clavio M; Miglino M; Lemoli RM; Gobbi M
Biosci Trends; 2017 Mar; 11(1):110-114. PubMed ID: 28123146
[TBL] [Abstract][Full Text] [Related]
34. Health economic impact of high-dose versus standard-dose cytarabine induction chemotherapy for acute myeloid leukaemia.
Fedele PL; Avery S; Patil S; Spencer A; Haas M; Wei A
Intern Med J; 2014 Aug; 44(8):757-63. PubMed ID: 24863325
[TBL] [Abstract][Full Text] [Related]
35. Acute myeloid leukemia in Manitoba. The consequences of standard "7 + 3" remission-induction therapy followed by high dose cytarabine postremission consolidation for myelosuppression, infectious morbidity, and outcome.
Bow EJ; Kilpatrick MG; Scott BA; Clinch JJ; Cheang MS
Cancer; 1994 Jul; 74(1):52-60. PubMed ID: 8004583
[TBL] [Abstract][Full Text] [Related]
36. Fludarabine and cytarabine versus high-dose cytarabine in consolidation treatment of t(8; 21) acute myeloid leukemia: A prospective, randomized study.
Li R; Hu X; Wang L; Cheng H; Lv S; Zhang W; Wang J; Yang J; Song X
Am J Hematol; 2017 Jan; 92(1):12-17. PubMed ID: 27673579
[TBL] [Abstract][Full Text] [Related]
37. Transplantation of autologous peripheral blood progenitor cells procured after high-dose cytarabine-based consolidation chemotherapy for adults with secondary acute myelogenous leukemia in first remission.
Schiller G; Lee M; Paquette R; Sawyers C; Khoubian F; Territo M
Leuk Lymphoma; 1999 May; 33(5-6):475-84. PubMed ID: 10342575
[TBL] [Abstract][Full Text] [Related]
38. High-dose cytarabine (HD araC) in the treatment of leukemias: a review.
Reese ND; Schiller GJ
Curr Hematol Malig Rep; 2013 Jun; 8(2):141-8. PubMed ID: 23666364
[TBL] [Abstract][Full Text] [Related]
39. A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study.
Miyawaki S; Ohtake S; Fujisawa S; Kiyoi H; Shinagawa K; Usui N; Sakura T; Miyamura K; Nakaseko C; Miyazaki Y; Fujieda A; Nagai T; Yamane T; Taniwaki M; Takahashi M; Yagasaki F; Kimura Y; Asou N; Sakamaki H; Handa H; Honda S; Ohnishi K; Naoe T; Ohno R
Blood; 2011 Feb; 117(8):2366-72. PubMed ID: 21190996
[TBL] [Abstract][Full Text] [Related]
40. Cytarabine dose for acute myeloid leukemia.
Löwenberg B; Pabst T; Vellenga E; van Putten W; Schouten HC; Graux C; Ferrant A; Sonneveld P; Biemond BJ; Gratwohl A; de Greef GE; Verdonck LF; Schaafsma MR; Gregor M; Theobald M; Schanz U; Maertens J; Ossenkoppele GJ;
N Engl J Med; 2011 Mar; 364(11):1027-36. PubMed ID: 21410371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]